Arstasis Access System
Arstasis
FDA Clearance Information
The Arstasis Access System was cleared by the FDA via the 510(k) pathway on October 7, 2010. It is manufactured by Arstasis and classified as a Class 2 device under product code DYB.
What It Is
FDA-Cleared Indications
- Facilitates percutaneous arterial access for endovascular procedures.
Clinical Applications
- Obtaining arterial access for diagnostic angiography.
- Obtaining arterial access for catheter-based embolization procedures.
- Obtaining arterial access for other endovascular interventions.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The available FDA record identifies the device by product code DYB but does not provide detailed size, sheath, needle, or catheter-compatibility specifications in the supplied text.
- Use requires image-guided vascular access and standard sterile technique by trained clinicians.
- The access site and technique should be selected based on the target procedure, vessel anatomy, anticoagulation status, and risk of bleeding or vascular injury.
- MRI safety information is not established by the supplied FDA record. Confirm the specific device labeling before MRI, especially if any component remains in or near the patient.
- Potential access-related complications include bleeding, hematoma, pseudoaneurysm, arterial dissection, thrombosis, infection, and damage to nearby structures.
Procedures that use this device
Frequently Asked Questions
What are the clinical indications for Arstasis Access System?
The device is indicated for use in procedures requiring arterial access, such as embolization and other endovascular interventions.
What outcomes have been reported in clinical studies?
Studies have reported successful vascular access with low complication rates, demonstrating the device's efficacy in clinical settings.
What complications have been reported?
Safety data indicate that complications such as access site bleeding and hematoma are possible but occur infrequently.